Accrington, UK – National Care Group (“NCG”), a leading provider of care and support services, announces the acquisition of the Abbeyvale Care Centre (“Abbeyvale”). Financial details of the deal were not disclosed.
Cambridge, UK – As many as 800 asthma deaths a year in the UK could be prevented by a new generation of ‘smart inhalers’, however, data concerns could be holding back roll out, says medical device developer and manufacturer, Bespak.
Naarden, The Netherlands, and Munich, Germany, – Forbion, a leading European life sciences venture capital firm, today announces that it invested $15 million in the $54 million Series A financing in Gotham Therapeutics, a newly formed biotechnology company developing a novel drug class targeting RNA-modifying proteins.
Cambridge, UK – Abcam’s new phosphate buffered saline (PBS)-only recombinant antibodies are free from preservatives and stabilising agents, offering improved flexibility for researchers conducting more complex experiments.
Accrington, UK – National Care Group (“NCG”), a leading provider of care and support services, announces the acquisition of the Cleveland House business in Broadstairs, Kent. Financial details of the deal were not disclosed.
Sydney, Australia - Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced the appointment of Dr Josep Tabernero, the President of the European Society for Medical Oncology, to its Scientific Advisory Board.
Cambridge, UK: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces a trading update for the year ended 31 May 2018 and the period to 30 September 2018. The Company is seeing improving trading conditions following a year of structural change and investment.
Naarden, The Netherlands, and Munich, Germany – Forbion, a leading European life science venture capital firm, has today announced the final close of its new flagship fund, Forbion IV. The oversubscribed fund closed at EUR 360 million in capital commitments, significantly above its original target of EUR 250 million.
London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new game-changing test for bloodstream infections (BSI) that can lead to sepsis, was named ‘Most Innovative Team or Innovator of the Year’ at the inaugural 2018 Medtech Insight Awards.
LONDON, BOSTON, TOKYO — The global medtech industry is forecast to grow at a CAGR of 5.6% from 2017 to 2024 and reach $595 billion in sales by 2024, according to the latest report from Evaluate Ltd. Medtronic was the leading medtech company in 2017 with sales of $30 billion, and is forecast to retain the crown in 2024 with sales of nearly $39 billion. Of the remaining top five companies in 2017, Johnson & Johnson, Abbott Laboratories and Siemens Healthineers are forecast to retain their places in 2024; however, Becton Dickinson jumps three spots to edge out Phillips and claim the number five spot following its purchase of C.R. Bard.
HOUSTON and LONDON – Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma. This is the first time an engineered NKT cell therapy has been used in humans. Cell Medica is a clinical-stage biopharmaceutical company that is transforming the treatment of solid and hematological cancer by developing the next generation of CAR therapies.
Oxford, UK – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.
Cambridge, UK – Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed an antibody humanisation agreement with Tmunity Therapeutics (Tmunity), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen Receptor T Cell (CAR-T) therapies for the treatment of solid and hematological cancers.
Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, confirms that it has commenced its human study being carried out on its SkinBiotix® technology.
Copenhagen, Denmark - Xellia Pharmaceuticals (Xellia or the Company), a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, today announced that it has opened a new office in Buffalo Grove, near Chicago, Illinois to accommodate the Company’s expanding North American commercial organization.
Cambridge, United Kingdom – Congenica, the global diagnostic decision support platform provider, today announced it has entered into an agreement with a new strategic partner Digital China Health Technologies Cooperation Limited (DCHealth), further extending Congenica’s commitment to the Chinese market.
SYDNEY, Australia – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced the Phase 1b clinical trial of its HER-Vaxx cancer vaccine in HER-2 gastric cancer patients had completed recruitment.
Cambridge, UK – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Pavel Pisa, MD, PhD, has been appointed as Chief Medical Officer of the Company with immediate effect.
Cambridge, UK – F-star, a biopharmaceutical company developing novel bispecific antibodies, today announces the appointment of Nessan Bermingham, Ph.D. as Chairman of its Board of Directors. Nessan succeeds John Edwards who has been F-star’s Chairman for seven years and will remain as a non-executive director.
Cambridge, UK: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its operating company Feedback Medical Ltd has received an order from its South Korean distributor for TexRAD®, its patented image texture analysis technology, for the Samsung Medical Centre in Seoul.
Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures.